Beijing Tiantan Biological Products Co., Ltd. (SHA:600161)

Market Cap	29.17B -27.3%
Revenue (ttm)	6.17B +2.3%
Net Income	1.09B -29.6%
EPS	0.55 -29.5%
Shares Out	1.98B
PE Ratio	26.82
Forward PE	23.63
Dividend	0.20 (1.35%)
Ex-Dividend Date	Sep 25, 2025

Volume	4,121,054
Average Volume	8,905,499
Open	14.79
Previous Close	14.75
Day's Range	14.76 - 15.01
52-Week Range	14.50 - 22.46
Beta	0.28
RSI	36.47
Earnings Date	Mar 28, 2026

About SHA:600161

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for inje...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1966
• Employees: 5,298
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600161

Financial Performance

In 2025, SHA:600161's revenue was 6.17 billion, an increase of 2.26% compared to the previous year's 6.03 billion. Earnings were 1.09 billion, a decrease of -29.59%.